Liu Wei, Ling Jian-yu
Organ Transplantation Center, Renji Hospital, Shanghai Jiaotong University Medical School, Shanghai, China.
Zhonghua Yi Xue Za Zhi. 2009 Sep 29;89(36):2565-7.
To determine whether there was any lingering effect after discontinuing Zenapax in renal transplantation and investigate there was any alternative immunity-regulating pathway of Zenapax other than IL-2/IL-2R.
Thirty patients of renal transplantation were divided into 2 groups. One group of 15 received 2 dosages of induction therapy of Zenapax and another 15 regular immunosuppressive therapy. IL-2, IL-10, STAT5 and CD40L were tested followed up at 2 hours pre-transplantation, 1, 3 and 6 months post-transplantation.
The levels of IL-2 and STAT had no difference between the induction group and the control group. The level of IL-10 of induction group (59.4 +/- 7.7) ng/L was obviously higher than control group (36.8 +/- 8.4) ng/L at 3 months post-transplantation. CD40L level of induction group (10.6 +/- 3.6) was lower than control group (35.6 +/- 8.4) at 1 month post-transplantation.
Zenapax can reduce B-cell-mediated humoral immunity at 1 month post-transplantation through CD40L pathway.
确定肾移植停用赛尼哌后是否存在残留效应，并研究赛尼哌除IL-2/IL-2R之外是否存在其他免疫调节途径。
30例肾移植患者分为2组。一组15例接受2剂赛尼哌诱导治疗，另一组15例接受常规免疫抑制治疗。在移植前2小时、移植后1、3和6个月进行随访，检测IL-2、IL-10、STAT5和CD40L。
诱导组和对照组的IL-2和STAT水平无差异。移植后3个月，诱导组IL-10水平（59.4±7.7）ng/L明显高于对照组（36.8±8.4）ng/L。移植后1个月，诱导组CD40L水平（10.6±3.6）低于对照组（35.6±8.4）。
赛尼哌可在移植后1个月通过CD40L途径降低B细胞介导的体液免疫。
